MOUNJARO KWIKPEN Drug Patent Profile

Which patents cover Mounjaro Kwikpen, and when can generic versions of Mounjaro Kwikpen launch?

Mounjaro Kwikpen is a drug marketed by Eli Lilly And Co and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and fifty patent family members in forty-six countries.

The generic ingredient in MOUNJARO KWIKPEN is tirzepatide. One supplier is listed for this compound. Additional details are available on the tirzepatide profile page.

DrugPatentWatch^® Generic Entry Outlook for Mounjaro Kwikpen

Mounjaro Kwikpen was eligible for patent challenges on May 13, 2026.

Indicators of Generic Entry

Summary for MOUNJARO KWIKPEN

International Patents:	150
US Patents:	3
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for MOUNJARO KWIKPEN

MOUNJARO KWIKPEN is protected by nine US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	MOUNJARO KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-022	Jan 20, 2026		RX	Yes	Yes			Y	Y
Eli Lilly And Co	MOUNJARO KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-024	Jan 20, 2026		RX	Yes	Yes
Eli Lilly And Co	MOUNJARO KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-022	Jan 20, 2026		RX	Yes	Yes
Eli Lilly And Co	MOUNJARO KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-019	Jan 20, 2026		RX	Yes	Yes

International Patents for MOUNJARO KWIKPEN

See the table below for patents covering MOUNJARO KWIKPEN around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1115648
Japan	7844689
Eurasian Patent Organization	202092810
China	112512633

Supplementary Protection Certificates for MOUNJARO KWIKPEN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3242887	202340002	Slovenia		PRODUCT NAME: TIRZEPATIDE; NATIONAL AUTHORISATION NUMBER: EU/1/22/1685; DATE OF NATIONAL AUTHORISATION: 20220915; AUTHORITY FOR NATIONAL AUTHORISATION: EU
3242887	6/2023	Austria		PRODUCT NAME: TIRZEPATID UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/22/1685 (MITTEILUNG) 20220919
3242887	2023C/506	Belgium		PRODUCT NAME: TIRZEPATIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1685 20220919
3242887	2390005-3	Sweden		PRODUCT NAME: TIRZEPATIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/22/1685, 2022-09-19; RAETTAD SKYDDSTID FOER TILLAEGGSSKYDD'; PRV HAR I BESLUT DEN 8 JULI 2025 RAETTAT SKYDDSTIDEN I FOELJANDE TILLAEGGSSKYDD I ENLIGHET MED PMD:S BESLUT PMAE 7804/24: 2290016-1, 2090020-5, 2090055-1, 1590060-8, 1890030-8, 1990012-5, 2190017-0, 1690040-9, 1790035-8, 2390005-3, 1990013-3, 2090009-8

Investment Scenario and Fundamentals Analysis for MOUNJARO KWIKPEN

Last updated: March 7, 2026

What Is MOUNJARO KWIKPEN?

MOUNJARO KWIKPEN is a once-weekly injectable medication with the active ingredient tirzepatide. It is developed and marketed by Eli Lilly and Company for the treatment of type 2 diabetes mellitus. Tirzepatide acts as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is designed to improve glycemic control and promote weight loss.

Market Position and Potential

Market Size and Growth

The global type 2 diabetes market was valued at approximately $73 billion in 2021, with expected compound annual growth rate (CAGR) of 7% through 2030 [1].

Competitive Landscape

MOUNJARO KWIKPEN competes primarily with:

• Novo Nordisk’s semaglutide (Ozempic, Wegovy)
• Eli Lilly’s own dulaglutide (Trulicity)
• Other GLP-1 receptor agonists

The dual mechanism of tirzepatide positions it as a potentially superior agent for glycemic control and weight management.

Approval and Launch Timeline

• Approved by the U.S. Food and Drug Administration (FDA) in May 2022 for type 2 diabetes.
• Approved in multiple jurisdictions including the European Union.
• Commercial launch began in mid-2022, with rapid uptake due to its clinical profile.

Revenue and Market Penetration

Eli Lilly reported $644 million in sales for MOUNJARO (including the KWIKPEN formulation) in 2022, with guidance projecting sales exceeding $3 billion by the end of 2023 [2].

Key Investment Considerations

Clinical Data and Efficacy

• SURPASS-2 trial demonstrated tirzepatide’s superiority over semaglutide in glycemic control.
• Showed significant weight loss (average 12-14% of body weight).
• Favorable safety profile with gastrointestinal side effects similar to other GLP-1 agents.

Patent and Intellectual Property

• Patent protection extends to at least 2030, with potential extensions.
• No immediate generic threat; barrier to entry remains high.

Regulatory and Reimbursement Factors

• Approved under FDA's Fast Track program.
• Reimbursement status favorable in major markets, driven by evidence of clinical efficiency.

Manufacturing and Supply Chain

• Eli Lilly has invested in scaling manufacturing capacity.
• Supply chain risks are minimal but could be affected by global logistics issues.

Competitive Risks

• Other agents like semaglutide have similar efficacy.
• Potential new entrants and biosimilars could erode market share.

Pricing Strategy

• Premium pricing aligned with comparator GLP-1 therapies.
• Price elasticity influenced by insurance coverage and clinical differentiation.

SWOT Analysis

Strengths	Weaknesses
Superior efficacy in weight loss	Limited long-term real-world data
Established manufacturing capacity	Potential for gastrointestinal side effects
Strong patent protection	Dependence on Eli Lilly’s marketing capabilities

Opportunities	Threats
Expansion into obesity market	Competition from emerging therapies
Growth in type 2 diabetes prevalence	Regulatory delays or adverse safety data
Development of combination regimens	Biosimilar and generic entry

Financial and Investment Outlook

• Revenue projections assume continued rapid adoption.
• Profit margins expected to improve as manufacturing scales.
• Strategic partnerships and pipeline developments could augment growth.

Key Risks and Uncertainties

• Clinical trial outcomes for additional indications.
• Regulatory changes affecting pricing or approval.
• Competitive threats from biosimilars or double-acting molecules.

---

Key Takeaways

• MOUNJARO KWIKPEN is a high-growth, high-margin product in Eli Lilly's portfolio.
• Its superior clinical efficacy over existing GLP-1 therapies positions it as a potential market leader.
• Patent protection secures exclusivity until at least 2030.
• Growth depends on market penetration, reimbursement, and competitive landscape evolution.
• Investors should monitor clinical developments, regulatory decisions, and market share trends.

FAQs

Q1: What are the main therapeutic benefits of MOUNJARO KWIKPEN?
It offers improved glycemic control and significant weight reduction compared to other GLP-1 receptor agonists.

Q2: How does tirzepatide differ from other diabetes treatments?
It acts on both GIP and GLP-1 receptors, providing dual stimulation that results in better metabolic outcomes.

Q3: What are the major risks for investors?
Competitive entry of biosimilars, market share erosion, and potential regulatory challenges.

Q4: When is patent expiration expected?
Patents extend through at least 2030, with potential extensions.

Q5: What financial impact has MOUNJARO had on Eli Lilly?
It generated $644 million in 2022 revenue, with projections exceeding $3 billion in 2023.

---

References

[1] Grand View Research. (2022). "Diabetes Drugs Market Size, Share & Trends Analysis."
[2] Eli Lilly and Company. (2023). "Q1 2023 Financial Results."